[1] Kivi, M., Aspects of Helicobacter pylori transmission. 2005: Karolinska Institutet (Sweden).
[2] Marshall, B.J., et al., Attempt to fulfil Koch's postulates for pyloric Campylobacter. Medical Journal of Australia, 1985. 142(8): p. 436-439.
[3] Hooi, J.K., et al., Global prevalence of Helicobacter pylori infection: systematic review and meta-analysis. Gastroenterology, 2017. 153(2): p. 420-429.
[4] Parsonnet, J., et al., Helicobacter pylori infection and gastric lymphoma. New England Journal of Medicine, 1994. 330(18): p. 1267-1271.
[5] Fischbach, W., Gastric mucosal-associated lymphoid tissue lymphoma. Gastroenterology Clinics, 2013. 42(2): p. 371-380.
[6] Backert, S. and M. Clyne, Pathogenesis of Helicobacter pylori infection. Helicobacter, 2011. 16: p. 19-25.
[7] Marshall, B. and J.R. Warren, Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. The lancet, 1984. 323(8390): p. 1311-1315.
[8] Solnick, J.V. and D.B. Schauer, Emergence of diverse Helicobacter species in the pathogenesis of gastric and enterohepatic diseases. Clinical microbiology reviews, 2001. 14(1): p. 59-97.
[9] Mladenova, I. and M. Durazzo, Transmission of Helicobacter pylori. Minerva gastroenterologica e dietologica, 2018. 64(3): p. 251-254.
[10] Oona, M., et al., Helicobacter pylori infection in children in Estonia: decreasing seroprevalence during the 11‐year period of profound socioeconomic changes. Helicobacter, 2004. 9(3): p. 233-241.
[11] Bürgers, R., et al., Helicobacter pylori in human oral cavity and stomach. European journal of oral sciences, 2008. 116(4): p. 297-304.
[12] Stefano, K., et al., Helicobacter pylori, transmission routes and recurrence of infection: state of the art. Acta Bio Medica: Atenei Parmensis, 2018. 89(Suppl 8): p. 72.
[13] Song, Q., et al., Helicobacter pylori in the Oral Cavity. Digestive diseases and sciences, 2000. 45(11): p. 2162-2167.
[14] Yee, J.K., Are the view of Helicobacter pylori colonized in the oral cavity an illusion? Experimental & Molecular Medicine, 2017. 49(11): p. e397-e397.
[15] Gebara, E., et al., Persistence of Helicobacter pylori in the oral cavity after systemic eradication therapy. Journal of clinical periodontology, 2006. 33(5): p. 329-333.
[16] Kivi, M.r., et al., Concordance of Helicobacter pylori strains within families. Journal of clinical microbiology, 2003. 41(12): p. 5604-5608.
[17] Queralt, N., R. Bartolome, and R. Araujo, Detection of Helicobacter pylori DNA in human faeces and water with different levels of faecal pollution in the north‐east of Spain. Journal of applied microbiology, 2005. 98(4): p. 889-895.
[18] Bui, D., et al., Serologic evidence for fecal–oral transmission of Helicobacter pylori. The American journal of tropical medicine and hygiene, 2016. 94(1): p. 82.
[19] Santiago, P., Y. Moreno, and M.A. Ferrús, Identification of viable Helicobacter pylori in drinking water supplies by cultural and molecular techniques. Helicobacter, 2015. 20(4): p. 252-259.
[20] Adams, B., T. Bates, and J. Oliver, Survival of Helicobacter pylori in a natural freshwater environment. Applied and environmental microbiology, 2003. 69(12): p. 7462-7466.
[21] Klein, P.D., et al., Water source as risk factor for Helicobacter pylori infection in Peruvian children. The Lancet, 1991. 337(8756): p. 1503-1506.
[22] Salih, B.A., Helicobacter pylori infection in developing countries: the burden for how long? Saudi journal of gastroenterology: official journal of the Saudi Gastroenterology Association, 2009. 15(3): p. 201.
[23] Goodman, K.J., et al., Helicobacter pylori infection in the Colombian Andes: a population-based study of transmission pathways. American journal of epidemiology, 1996. 144(3): p. 290-299.
[24] ZHANG, Y.Y., et al., ‘true’re‐infection of Helicobacter pylori after successful eradication–worldwide annual rates, risk factors and clinical implications. Alimentary pharmacology & therapeutics, 2009. 29(2): p. 145-160.
[25] Momtaz, H., et al., Study of Helicobacter pylori genotype status in cows, sheep, goats and human beings. BMC gastroenterology, 2014. 14(1): p. 1-7.
[26] Payão, S.L.M. and L.T. Rasmussen, Helicobacter pylori and its reservoirs: A correlation with the gastric infection. World journal of gastrointestinal pharmacology and therapeutics, 2016. 7(1): p. 126.
[27] Engstrand, L., et al., Inoculation of barrier-born pigs with Helicobacter pylori: a useful animal model for gastritis type B. Infection and Immunity, 1990. 58(6): p. 1763-1768.
[28] Handt, L.K., et al., Helicobacter pylori isolated from the domestic cat: public health implications. Infection and immunity, 1994. 62(6): p. 2367-2374.
[29] Rodrigues, M.N., et al., Prevalence of Helicobacter pylori infection in children from an urban community in north-east Brazil and risk factors for infection. European journal of gastroenterology & hepatology, 2004. 16(2): p. 201-205.
[30] Glynn, M.K., et al., Seroincidence of Helicobacter pylori infection in a cohort of rural Bolivian children: acquisition and analysis of possible risk factors. Clinical Infectious Diseases, 2002. 35(9): p. 1059-1065.
[31] Rothenbacher, D., et al., Role of infected parents in transmission of Helicobacter pylori to their children. The Pediatric infectious disease journal, 2002. 21(7): p. 674-679.
[32] Rocha, G.A., et al., Transmission of Helicobacter pylori infection in families of preschool‐aged children from Minas Gerais, Brazil. Tropical Medicine & International Health, 2003. 8(11): p. 987-991.
[33] Malaty, H.M., et al., Evidence from a nine-year birth cohort study in Japan of transmission pathways of Helicobacter pylori infection. Journal of clinical microbiology, 2000. 38(5): p. 1971-1973.
[34] Kivi, M., et al., Helicobacter pylori status in family members as risk factors for infection in children. Epidemiology & Infection, 2005. 133(4): p. 645-652.
[35] Lambert, J.R., et al., High Prevalence of Helicobacter pylori Antibodies in an Institutionalized Population: Evidence for Person--to--Person Transmission. American Journal of Gastroenterology (Springer Nature), 1995. 90(12).
[36] Tindberg, Y., et al., Helicobacter pylori infection in Swedish school children: lack of evidence of child-to-child transmission outside the family. Gastroenterology, 2001. 121(2): p. 310-316.
[37] Tsai, C.J., et al., Helicobacter pylori infection in different generations of Hispanics in the San Francisco Bay Area. American journal of epidemiology, 2005. 162(4): p. 351-357.
[38] Woodward, M., C. Morrison, and K. McColl, An investigation into factors associated with Helicobacter pylori infection. Journal of clinical epidemiology, 2000. 53(2): p. 175-181.
[39] Brenner, H., et al., Active infection with Helicobacter pylori in healthy couples. Epidemiology & Infection, 1999. 122(1): p. 91-95.
[40] Mendall, M., et al., Childhood living conditions and Helicobacter pylori seropositivity in adult life. The Lancet, 1992. 339(8798): p. 896-897.
[41] Brown, L.M., et al., Helicobacter pylori infection in rural China: demographic, lifestyle and environmental factors. International journal of epidemiology, 2002. 31(3): p. 638-645.
[42] Kuepper‐Nybelen, J., et al., Patterns of alcohol consumption and Helicobacter pylori infection: results of a population‐based study from Germany among 6545 adults. Alimentary pharmacology & therapeutics, 2005. 21(1): p. 57-64.
[43] Salaün, L., S. Ayraud, and N.J. Saunders, Phase variation mediated niche adaptation during prolonged experimental murine infection with Helicobacter pylori. Microbiology, 2005. 151(3): p. 917-923.
[44] Malaty, H.M., et al., Age at acquisition of Helicobacter pylori infection: a follow-up study from infancy to adulthood. The Lancet, 2002. 359(9310): p. 931-935.
[45] Aspholm-Hurtig, M., et al., Functional adaptation of BabA, the H. pylori ABO blood group antigen binding adhesin. Science, 2004. 305(5683): p. 519-522.
[46] Rothenbacher, D., et al., Role of Lewis A and Lewis B blood group antigens in Helicobacter pylori infection. Helicobacter, 2004. 9(4): p. 324-329.
[47] Yamaoka, Y., et al., Helicobacter pylori infection in mice: role of outer membrane proteins in colonization and inflammation. Gastroenterology, 2002. 123(6): p. 1992-2004.
[48] Magnusson, P.K., et al., Gastric cancer and human leukocyte antigen: distinct DQ and DR alleles are associated with development of gastric cancer and infection by Helicobacter pylori. Cancer research, 2001. 61(6): p. 2684-2689.
[49] Hartland, S., et al., A functional polymorphism in the interleukin-1 receptor-1 gene is associated with increased risk of Helicobacter pylori infection but not with gastric cancer. Digestive diseases and sciences, 2004. 49(9): p. 1545-1550.
[50] Björkholm, B., et al., Gnotobiotic transgenic mice reveal that transmission of Helicobacter pylori is facilitated by loss of acid-producing parietal cells in donors and recipients. Microbes and infection, 2004. 6(2): p. 213-220.
[51] Salama, N.R., B. Shepherd, and S. Falkow, Global transposon mutagenesis and essential gene analysis of Helicobacter pylori. Journal of bacteriology, 2004. 186(23): p. 7926-7935.
[52] Perez-Perez, G., et al., Evidence that cagA+ Helicobacter pylori strains are disappearing more rapidly than cagA− strains. Gut, 2002. 50(3): p. 295-298.
[53] Nilsson, C., et al., Correlation between cag pathogenicity island composition and Helicobacter pylori-associated gastroduodenal disease. Infection and immunity, 2003. 71(11): p. 6573-6581.
[54] Cardenas, V.M., et al., Iron deficiency and Helicobacter pylori infection in the United States. American journal of epidemiology, 2006. 163(2): p. 127-134.
[55] Everhart, J.E., et al., Seroprevalence and ethnic differences in Helicobacter pylori infection among adults in the United States. The Journal of infectious diseases, 2000. 181(4): p. 1359-1363.
[56] Goh, K.-L. and N. Parasakthi, The racial cohort phenomenon: seroepidemiology of Helicobacter pylori infection in a multiracial South-East Asian country. European journal of gastroenterology & hepatology, 2001. 13(2): p. 177-183.
[57] Asaka, M., et al., Gastric cancer. Helicobacter pylori: physiology and genetics, 2001: p. 481-498.
[58] Yeh, J.M., et al., Exploring the cost‐effectiveness of Helicobacter pylori screening to prevent gastric cancer in China in anticipation of clinical trial results. International journal of cancer, 2009. 124(1): p. 157-166.
[59] Torres, J., et al., A comprehensive review of the natural history of Helicobacter pylori infection in children. Archives of medical research, 2000. 31(5): p. 431-469.
[60] Agarwal, P.K., et al., Prevalence of Helicobacter pylori infection in upper gastrointestinal tract disorders (dyspepsia) patients visiting outpatient department of a hospital of North India. Journal of family medicine and primary care, 2018. 7(3): p. 577.
[61] Lacy, B.E. and J. Rosemore, Helicobacter pylori: ulcers and more: the beginning of an era. The Journal of nutrition, 2001. 131(10): p. 2789S-2793S.
[62] Gold, B.D., Helicobacter pylori infection in children. Current Problems in Pediatrics, 2001. 31(8): p. 247-266.
[63] De Oliveira, A.M.R., et al., Seroconversion for Helicobacter pylori in adults from Brazil. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1999. 93(3): p. 261-263.
[64] Ernst, P.B. and B.D. Gold, The disease spectrum of Helicobacter pylori: the immunopathogenesis of gastroduodenal ulcer and gastric cancer. Annual review of microbiology, 2000. 54: p. 615.
[65] Kuipers, E., Exploring the link between Helicobacter pylori and gastric cancer. Alimentary pharmacology & therapeutics, 1999. 13: p. 3-11.
[66] Kuipers, E., J. Thijs, and H. Festen, The prevalence of Helicobacter pylori in peptic ulcer disease. Alimentary pharmacology & therapeutics, 1995. 9: p. 59-69.
[67] Kusters, J.G., A.H. Van Vliet, and E.J. Kuipers, Pathogenesis of Helicobacter pylori infection. Clinical microbiology reviews, 2006. 19(3): p. 449-490.
[68] Maaroos, H.-I., et al., An 18-year follow-up study of chronic gastritis and Helicobacter pylori: association of CagA positivity with development of atrophy and activity of gastritis. Scandinavian journal of gastroenterology, 1999. 34(9): p. 864-869.
[69] Flores, S.E., et al., Helicobacter pylori infection perturbs iron homeostasis in gastric epithelial cells. PLoS One, 2017. 12(9): p. e0184026.
[70] Kato, S., et al., Helicobacter pylori sabA gene is associated with iron deficiency anemia in childhood and adolescence. PloS one, 2017. 12(8): p. e0184046.
[71] Rockey, D.C., et al., AGA technical review on gastrointestinal evaluation of iron deficiency anemia. Gastroenterology, 2020. 159(3): p. 1097-1119.
[72] Sipponen, P., et al., Prevalence of low vitamin B12 and high homocysteine in serum in an elderly male population: association with atrophic gastritis and Helicobacter pylori infection. Scandinavian journal of gastroenterology, 2003. 38(12): p. 1209-1216.
[73] Correa, P., M.B. Piazuelo, and M.C. Camargo, The future of gastric cancer prevention. Gastric cancer, 2004. 7(1): p. 9-16.
[74] Uemura, N., et al., Helicobacter pylori infection and the development of gastric cancer. New England journal of medicine, 2001. 345(11): p. 784-789.
[75] Blaser, M.J. and J.C. Atherton, Helicobacter pylori persistence: biology and disease. The Journal of clinical investigation, 2004. 113(3): p. 321-333.
[76] Danesh, J., R. Collins, and R. Peto, Chronic infections and coronary heart disease: is there a link? The lancet, 1997. 350(9075): p. 430-436.
[77] El-Omar, E.M., et al., Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature, 2000. 404(6776): p. 398-402.
[78] Eaton, K.A. and S. Krakowka, Effect of gastric pH on urease-dependent colonization of gnotobiotic piglets by Helicobacter pylori. Infection and immunity, 1994. 62(9): p. 3604-3607.
[79] Sobala, G., et al., Acute Helicobacter pylori infection: clinical features, local and systemic immune response, gastric mucosal histology, and gastric juice ascorbic acid concentrations. Gut, 1991. 32(11): p. 1415-1418.
[80] Kuipers, E.J., et al., Increase of Helicobacter pylori--Associated Corpus Gastritis during Acid Suppressive Therapy: Implications for Long--Term Safety. American Journal of Gastroenterology (Springer Nature), 1995. 90(9).
[81] El-Omar, E.M., et al., Helicobacter pylori infection and chronic gastric acid hyposecretion. Gastroenterology, 1997. 113(1): p. 15-24.
[82] Consensus, N., Helicobacter pylori in peptic ulcer disease. JAMA, 1994. 272: p. 65-69.
[83] Suerbaum, S. and P. Michetti, Helicobacter pylori infection. New England Journal of Medicine, 2002. 347(15): p. 1175-1186.
[84] Rothenbacher, D. and H. Brenner, Burden of Helicobacter pylori and H. pylori-related diseases in developed countries: recent developments and future implications. Microbes and Infection, 2003. 5(8): p. 693-703.
[85] Pereira, M.-I. and J.A. Medeiros, Role of Helicobacter pylori in gastric mucosa-associated lymphoid tissue lymphomas. World journal of gastroenterology: WJG, 2014. 20(3): p. 684.
[86] Zucca, E., et al., Gastric marginal zone lymphoma of MALT type: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 2013. 24: p. vi144-vi148.
[87] Malfertheiner, P., et al., Management of Helicobacter pylori infection—the Maastricht IV/Florence consensus report. Gut, 2012. 61(5): p. 646-664.
[88] Floch, P., F. Mégraud, and P. Lehours, Helicobacter pylori strains and gastric MALT lymphoma. Toxins, 2017. 9(4): p. 132.
[89] Cammarota, G., et al., Helicobacter pylori reinfection and rapid relapse of low-grade B-cell gastric lymphoma. The Lancet, 1995. 345(8943): p. 192.
[90] Talley, N.J. and R.H. Hunt, What role does Helicobacter pylori play in dyspepsia and nonulcer dyspepsia? Arguments for and against H. pylori being associated with dyspeptic symptoms. Gastroenterology, 1997. 113(6): p. S67-S77.
[91] Moayyedi, P., et al., Eradication of Helicobacter pylori for non‐ulcer dyspepsia. Cochrane Database of Systematic Reviews, 2005(2).
[92] Öztekin, M., et al., Overview of Helicobacter pylori Infection: Clinical Features, treatment, and nutritional aspects. Diseases, 2021. 9(4): p. 66.
[93] Wroblewski, L.E. and R.M. Peek, Helicobacter pylori, cancer, and the gastric microbiota. Stem Cells, Pre-neoplasia, and Early Cancer of the Upper Gastrointestinal Tract, 2016: p. 393-408.
[94] Eaton, K., D. Morgan, and S. Krakowka, Motility as a factor in the colonisation of gnotobiotic piglets by Helicobacter pylori. Journal of Medical Microbiology, 1992. 37(2): p. 123-127.
[95] De Brito, B.B., et al., Pathogenesis and clinical management of Helicobacter pylori gastric infection. World journal of gastroenterology, 2019. 25(37): p. 5578.
[96] Shibayama, K., et al., Metabolism of glutamine and glutathione via γ‐glutamyltranspeptidase and glutamate transport in Helicobacter pylori: possible significance in the pathophysiology of the organism. Molecular microbiology, 2007. 64(2): p. 396-406.
[97] Malfertheiner, P., M. Venerito, and C. Schulz, Helicobacter pylori infection: new facts in clinical management. Current treatment options in gastroenterology, 2018. 16(4): p. 605-615.
[98] Abadi, A.T.B. and J.G. Kusters, Management of Helicobacter pylori infections. BMC gastroenterology, 2016. 16(1): p. 1-4.
[99] Safavi, M., R. Sabourian, and A. Foroumadi, Treatment of Helicobacter pylori infection: Current and future insights. World journal of clinical cases, 2016. 4(1): p. 5.
[100] Ayala, G., et al., Exploring alternative treatments for Helicobacter pylori infection. World journal of gastroenterology: WJG, 2014. 20(6): p. 1450.
[101] Meyer-Rosberg, K., et al., The effect of environmental pH on the proton motive force of Helicobacter pylori. Gastroenterology, 1996. 111(4): p. 886-900.
[102] Turbett, G.R., et al., Purification and characterization of the urease enzymes of Helicobacter species from humans and animals. Infection and immunity, 1992. 60(12): p. 5259-5266.
[103] Ha, N.-C., et al., Supramolecular assembly and acid resistance of Helicobacter pylori urease. Nature structural biology, 2001. 8(6): p. 505-509.
[104] Dunn, B.E., et al., Purification and characterization of urease from Helicobacter pylori. Journal of Biological Chemistry, 1990. 265(16): p. 9464-9469.
[105] Clyne, M., A. Labigne, and B. Drumm, Helicobacter pylori requires an acidic environment to survive in the presence of urea. Infection and immunity, 1995. 63(5): p. 1669-1673.
[106] Jones, M.D., Y. Li, and D.B. Zamble, Acid-responsive activity of the Helicobacter pylori metalloregulator NikR. Proceedings of the National Academy of Sciences, 2018. 115(36): p. 8966-8971.
[107] Wen, G., et al., Helicobacter pylori infection downregulates duodenal CFTR and SLC26A6 expressions through TGFβ signaling pathway. BMC microbiology, 2018. 18(1): p. 1-11.
[108] Hathroubi, S., J. Zerebinski, and K.M. Ottemann, Helicobacter pylori biofilm involves a multigene stress-biased response, including a structural role for flagella. MBio, 2018. 9(5): p. e01973-18.
[109] Dunne, C., B. Dolan, and M. Clyne, Factors that mediate colonization of the human stomach by Helicobacter pylori. World journal of gastroenterology, 2014. 20(19): p. 5610-5624.
[110] Chmiela, M., N. Walczak, and K. Rudnicka, Helicobacter pylori outer membrane vesicles involvement in the infection development and Helicobacter pylori-related diseases. Journal of biomedical science, 2018. 25(1): p. 1-11.
[111] Ronci, M., et al., Identification and characterization of the α-CA in the outer membrane vesicles produced by Helicobacter pylori. Journal of enzyme inhibition and medicinal chemistry, 2019. 34(1): p. 189-195.
[112] Turner, L., et al., Helicobacter pylori outer membrane vesicle size determines their mechanisms of host cell entry and protein content. Frontiers in immunology, 2018. 9: p. 1466.
[113] Tsutsumi, R., et al., Attenuation of Helicobacter pylori CagA· SHP-2 signaling by interaction between CagA and C-terminal Src kinase. Journal of Biological Chemistry, 2003. 278(6): p. 3664-3670.
[114] Fischer, W., Assembly and molecular mode of action of the Helicobacter pylori Cag type IV secretion apparatus. The FEBS journal, 2011. 278(8): p. 1203-1212.
[115] Suarez, G., et al., Genetic Manipulation of Helicobacter pylori Virulence Function by Host Carcinogenic PhenotypesH. pylori, Gastric Cancer, CagY. Cancer research, 2017. 77(9): p. 2401-2412.
[116] Kanada, R., et al., Genotyping of the cagA gene of Helicobacter pylori on immunohistochemistry with East Asian CagA‐specific antibody. Pathology International, 2008. 58(4): p. 218-225.
[117] Yamaoka, Y., et al., Molecular epidemiology of Helicobacter pylori: separation of H. pylori from East Asian and non-Asian countries. Epidemiology & Infection, 2000. 124(1): p. 91-96.
[118] Basso, D., et al., Clinical relevance of Helicobacter pylori cagA and vacA gene polymorphisms. Gastroenterology, 2008. 135(1): p. 91-99.
[119] Queiroz, D.M., et al., Higher frequency of cagA EPIYA-C phosphorylation sites in H. pylori strains from first-degree relatives of gastric cancer patients. BMC gastroenterology, 2012. 12(1): p. 1-7.
[120] Higashi, H., et al., SHP-2 tyrosine phosphatase as an intracellular target of Helicobacter pylori CagA protein. Science, 2002. 295(5555): p. 683-686.
[121] Atherton, J., et al., Clinical and pathological importance of heterogeneity in vacA, the vacuolating cytotoxin gene of Helicobacter pylori. Gastroenterology, 1997. 112(1): p. 92-99.
[122] Djekic, A. and A. Müller, The immunomodulator VacA promotes immune tolerance and persistent Helicobacter pylori infection through its activities on T-cells and antigen-presenting cells. Toxins, 2016. 8(6): p. 187.
[123] Boquet, P. and V. Ricci, Intoxication strategy of Helicobacter pylori VacA toxin. Trends in microbiology, 2012. 20(4): p. 165-174.
[124] Lu, H., et al., Duodenal ulcer promoting gene of Helicobacter pylori. Gastroenterology, 2005. 128(4): p. 833-848.
[125] Yamaoka, Y., Roles of the plasticity regions of Helicobacter pylori in gastroduodenal pathogenesis. Journal of medical microbiology, 2008. 57(Pt 5): p. 545.
[126] Queiroz, D.M., et al., dupA polymorphisms and risk of Helicobacter pylori-associated diseases. International Journal of Medical Microbiology, 2011. 301(3): p. 225-228.
[127] Yamaoka, Y., D.H. Kwon, and D.Y. Graham, AM r 34,000 proinflammatory outer membrane protein (oipA) of Helicobacter pylori. Proceedings of the National Academy of Sciences, 2000. 97(13): p. 7533-7538.
[128] Sallas, M.L., et al., Status (on/off) of oipA gene: Their associations with gastritis and gastric cancer and geographic origins. Archives of microbiology, 2019. 201(1): p. 93-97.
[129] Franco, A.T., et al., Regulation of gastric carcinogenesis by Helicobacter pylori virulence factors. Cancer research, 2008. 68(2): p. 379-387.
[130] Kim, K.-M., et al., Helicobacter pylori γ-glutamyltranspeptidase induces cell cycle arrest at the G1-S phase transition. The Journal of Microbiology, 2010. 48(3): p. 372-377.
[131] Oertli, M., et al., Helicobacter pylori γ-glutamyl transpeptidase and vacuolating cytotoxin promote gastric persistence and immune tolerance. Proceedings of the National Academy of Sciences, 2013. 110(8): p. 3047-3052.
[132] Gong, M., et al., Helicobacter pylori γ-glutamyl transpeptidase is a pathogenic factor in the development of peptic ulcer disease. Gastroenterology, 2010. 139(2): p. 564-573.
[133] Crabtree, J., et al., Immune responses to Helicobacter pylori in children with recurrent abdominal pain. Journal of clinical pathology, 1991. 44(9): p. 768-771.
[134] Smith, S.M., Role of Toll-like receptors in Helicobacter pylori infection and immunity. World journal of gastrointestinal pathophysiology, 2014. 5(3): p. 133.
[135] Smith, M.F., et al., Toll-like receptor (TLR) 2 and TLR5, but not TLR4, are required for Helicobacter pylori-induced NF-κB activation and chemokine expression by epithelial cells. Journal of Biological Chemistry, 2003. 278(35): p. 32552-32560.
[136] Alandiyjany, M.N., et al., A role for the tfs3 ICE-encoded type IV secretion system in pro-inflammatory signalling by the Helicobacter pylori Ser/Thr kinase, CtkA. PLoS One, 2017. 12(7): p. e0182144.
[137] Wilson, K.T., et al., Helicobacter pylori stimulates inducible nitric oxide synthase expression and activity in a murine macrophage cell line. Gastroenterology, 1996. 111(6): p. 1524-1533.
[138] Lundgren, A., et al., Helicobacter pylori-specific CD4+ CD25high regulatory T cells suppress memory T-cell responses to H. pylori in infected individuals. Infection and immunity, 2003. 71(4): p. 1755-1762.
[139] Crabtree, J., et al., Mucosal tumour necrosis factor alpha and interleukin-6 in patients with Helicobacter pylori associated gastritis. Gut, 1991. 32(12): p. 1473-1477.
[140] De Melo, F.F., et al., A regulatory instead of an IL-17 T response predominates in Helicobacter pylori-associated gastritis in children. Microbes and Infection, 2012. 14(4): p. 341-347.
[141] Nurgalieva, Z.Z., et al., B-cell and T-cell immune responses to experimental Helicobacter pylori infection in humans. Infection and immunity, 2005. 73(5): p. 2999-3006.
[142] El-Serag, H.B., et al., Houston consensus conference on testing for Helicobacter pylori infection in the United States. Clinical Gastroenterology and Hepatology, 2018. 16(7): p. 992-1002. e6.
[143] Dore, M.P., et al., Dyspepsia: when and how to test for Helicobacter pylori infection. Gastroenterology research and practice, 2016. 2016.
[144] Wang, Y.-K., et al., Diagnosis of Helicobacter pylori infection: Current options and developments. World Journal of Gastroenterology: WJG, 2015. 21(40): p. 11221.
[145] Pichon, M., et al., Diagnostic accuracy of a noninvasive test for detection of Helicobacter pylori and resistance to clarithromycin in stool by the Amplidiag H. pylori+ ClariR real-time PCR assay. Journal of clinical microbiology, 2020. 58(4): p. e01787-19.
[146] Ferwana, M., et al., Accuracy of urea breath test in Helicobacter pylori infection: meta-analysis. World journal of gastroenterology: WJG, 2015. 21(4): p. 1305.
[147] Mezmale, L., et al., Epidemiology of Helicobacter pylori. Helicobacter, 2020. 25: p. e12734.
[148] Leal, Y.A., et al., 13C‐urea breath test for the diagnosis of Helicobacter pylori infection in children: a systematic review and meta‐analysis. Helicobacter, 2011. 16(4): p. 327-337.
[149] Peng, N.-J., et al., Clinical significance of oral urease in diagnosis of Helicobacter pylori infection by [13C] urea breath test. Digestive diseases and sciences, 2001. 46(8): p. 1772-1778.
[150] Ricci, C., J. Holton, and D. Vaira, Diagnosis of Helicobacter pylori: invasive and non-invasive tests. Best Practice & Research Clinical Gastroenterology, 2007. 21(2): p. 299-313.
[151] Bordin, D.S., et al., Current Helicobacter pylori diagnostics. Diagnostics, 2021. 11(8): p. 1458.
[152] Dore, M.P., et al., Characterization of a culture method to recover Helicobacter pylori from the feces of infected patients. Helicobacter, 2000. 5(3): p. 165-168.
[153] Gisbert, J.P., F. De La Morena, and V. Abraira, Accuracy of monoclonal stool antigen test for the diagnosis of H. pylori infection: a systematic review and meta-analysis. Official journal of the American College of Gastroenterology| ACG, 2006. 101(8): p. 1921-1930.
[154] Guarner, J., et al., Helicobacter pylori diagnostic tests in children: review of the literature from 1999 to 2009. European journal of pediatrics, 2010. 169(1): p. 15-25.
[155] Dore, M.P. and G.M. Pes, What is new in Helicobacter pylori diagnosis. An overview. Journal of Clinical Medicine, 2021. 10(10): p. 2091.
[156] Best, L.M., et al., Non‐invasive diagnostic tests for Helicobacter pylori infection. Cochrane Database of Systematic Reviews, 2018(3).
[157] Malfertheiner, P., et al., European helicobacter and microbiota study group and consensus panel. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut, 2017. 66(1): p. 6-30.
[158] Okubo, M., et al., Changes in gastric mucosal patterns seen by magnifying NBI during H. pylori eradication. Journal of gastroenterology, 2011. 46(2): p. 175-182.
[159] Stefano, K., et al., Non-invasive tests for the diagnosis of helicobacter pylori: state of the art. Acta Bio Medica: Atenei Parmensis, 2018. 89(Suppl 8): p. 58.
[160] Tu, H., et al., Serum anti-Helicobacter pylori immunoglobulin G titer correlates with grade of histological gastritis, mucosal bacterial density, and levels of serum biomarkers. Scandinavian journal of gastroenterology, 2014. 49(3): p. 259-266.
[161] Dixon, M.F., et al., Classification and grading of gastritis: the updated Sydney system. The American journal of surgical pathology, 1996. 20(10): p. 1161-1181.
[162] Varbanova, M., et al., Impact of the angulus biopsy for the detection of gastric preneoplastic conditions and gastric cancer risk assessment. Journal of clinical pathology, 2016. 69(1): p. 19-25.
[163] Graham, D., et al., Early events in proton pump inhibitor‐associated exacerbation of corpus gastritis. Alimentary pharmacology & therapeutics, 2003. 17(2): p. 193-200.
[164] Glickman, J.N., et al., Helicobacter infections with rare bacteria or minimal gastritis: expecting the unexpected. Digestive and Liver Disease, 2015. 47(7): p. 549-555.
[165] Snead, D.R., et al., Validation of digital pathology imaging for primary histopathological diagnosis. Histopathology, 2016. 68(7): p. 1063-1072.
[166] Benoit, A., N. Hoyeau, and J.-F. Fléjou. Diagnosis of Helicobacter pylori infection on gastric biopsies: Standard stain, special stain or immunohistochemistry? in Annales de Pathologie. 2018.
[167] Godbole, G., F. Mégraud, and E. Bessède, Diagnosis of Helicobacter pylori infection. Helicobacter, 2020. 25: p. e12735.
[168] Seo, J.-H., et al., Limitations of urease test in diagnosis of pediatric Helicobacter pylori infection. World Journal of Clinical Pediatrics, 2015. 4(4): p. 143.
[169] Cho, J.-H., et al., Factors for improving the diagnostic efficiency of the rapid urease test from the gastric corpus. Scandinavian Journal of Gastroenterology, 2017. 52(12): p. 1320-1325.
[170] Parihar, V., et al., A combined antral and corpus rapid urease testing protocol can increase diagnostic accuracy despite a low prevalence of Helicobacter pylori infection in patients undergoing routine gastroscopy. United European Gastroenterology Journal, 2015. 3(5): p. 432-436.
[171] Dechant, F.-X., et al., Accuracy of different rapid urease tests in comparison with histopathology in patients with endoscopic signs of gastritis. Digestion, 2020. 101(2): p. 184-190.
[172] Kuhns, L.G., et al., Carbon fixation driven by molecular hydrogen results in chemolithoautotrophically enhanced growth of Helicobacter pylori. Journal of Bacteriology, 2016. 198(9): p. 1423-1428.
[173] Pohl, D., et al., Review of current diagnostic methods and advances in Helicobacter pylori diagnostics in the era of next generation sequencing. World journal of gastroenterology, 2019. 25(32): p. 4629.
[174] Omori, T., et al., Correlation between magnifying narrow band imaging and histopathology in gastric protruding/or polypoid lesions: a pilot feasibility trial. BMC gastroenterology, 2012. 12(1): p. 1-7.
[175] Shukla, R., et al., Endoscopic imaging: How far are we from real-time histology? World Journal of Gastrointestinal Endoscopy, 2011. 3(10): p. 183.
[176] Alaboudy, A.A., et al., Conventional narrow-band imaging has good correlation with histopathological severity of Helicobacter pylori gastritis. Digestive diseases and sciences, 2011. 56(4): p. 1127-1130.
[177] Kawamura, M., et al., Topographic differences in gastric micromucosal patterns observed by magnifying endoscopy with narrow band imaging. Journal of gastroenterology and hepatology, 2011. 26(3): p. 477-483.
[178] Ji, R., et al., Mucosal barrier defects in gastric intestinal metaplasia: in vivo evaluation by confocal endomicroscopy. Gastrointestinal endoscopy, 2012. 75(5): p. 980-987.
[179] Neumann, H., et al., in vivo imaging by endocytoscopy. Alimentary pharmacology & therapeutics, 2011. 33(11): p. 1183-1193.
[180] Zhang, J.-G. and H.-F. Liu, Functional imaging and endoscopy. World journal of gastroenterology: WJG, 2011. 17(38): p. 4277.
[181] Kalach, N., et al., Usefulness of gastric biopsy–based real-time polymerase chain reaction for the diagnosis of Helicobacter pylori infection in children. Journal of Pediatric Gastroenterology and Nutrition, 2015. 61(3): p. 307-312.
[182] Ogaya, Y., et al., Detection of Helicobacter pylori DNA in inflamed dental pulp specimens from Japanese children and adolescents. Journal of medical microbiology, 2015. 64(1): p. 117-123.
[183] Ismail, H., et al., A newly developed nested PCR assay for the detection of Helicobacter pylori in the oral cavity. Journal of clinical gastroenterology, 2016. 50(1): p. 17-22.
[184] Zhou, L., et al., A creative Helicobacter pylori diagnosis scheme based on multiple genetic analysis system: qualification and quantitation. Helicobacter, 2015. 20(5): p. 343-352.
[185] Rabelo-Goncalves, E., et al., Evaluation of five DNA extraction methods for detection of H. pylori in formalin-fixed paraffin-embedded (FFPE) liver tissue from patients with hepatocellular carcinoma. Pathology-Research and Practice, 2014. 210(3): p. 142-146.
[186] Kim, J., et al., An appropriate cutoff value for determining the colonization of Helicobacter pylori by the pyrosequencing method: comparison with conventional methods. Helicobacter, 2015. 20(5): p. 370-380.
[187] Matsui, H., et al., Development of New PCR Primers by Comparative Genomics for the Detection of H elicobacter suis in Gastric Biopsy Specimens. Helicobacter, 2014. 19(4): p. 260-271.
[188] Fowsantear, W., et al., Comparative proteomics of Helicobacter species: the discrimination of gastric and enterohepatic Helicobacter species. Journal of Proteomics, 2014. 97: p. 245-255.
[189] Trespalacios, A.A., et al., Improved allele-specific PCR assays for detection of clarithromycin and fluoroquinolone resistant of Helicobacter pylori in gastric biopsies: identification of N87I mutation in GyrA. Diagnostic microbiology and infectious disease, 2015. 81(4): p. 251-255.
[190] Lee, J.W., et al., GenoType HelicoDR test in the determination of antimicrobial resistance of Helicobacter pylori in Korea. Scandinavian journal of gastroenterology, 2014. 49(9): p. 1058-1067.
[191] Malfertheiner, P., et al., Management of Helicobacter pylori infection—the Maastricht V/Florence consensus report. Gut, 2017. 66(1): p. 6-30.
[192] Murakami, K., et al., Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study. Gut, 2016. 65(9): p. 1439-1446.
[193] Molina-Infante, J. and J.P. Gisbert, Optimizing clarithromycin-containing therapy for Helicobacter pylori in the era of antibiotic resistance. World Journal of Gastroenterology: WJG, 2014. 20(30): p. 10338.
[194] Wang, L., et al., Ten-day bismuth-containing quadruple therapy is effective as first-line therapy for Helicobacter pylori–related chronic gastritis: a prospective randomized study in China. Clinical Microbiology and Infection, 2017. 23(6): p. 391-395.
[195] Muller, N., et al., Rescue therapy with bismuth-containing quadruple therapy in patients infected with metronidazole-resistant Helicobacter pylori strains. Clinics and research in hepatology and gastroenterology, 2016. 40(4): p. 517-524.
[196] Nishizawa, T., et al., Clarithromycin versus metronidazole as first-line helicobacter pylori eradication. Journal of clinical gastroenterology, 2015. 49(6): p. 468-471.
[197] Zullo, A., et al., Prevalence of lesions detected at upper endoscopy: an Italian survey. European Journal of Internal Medicine, 2014. 25(8): p. 772-776.
[198] Gisbert, J., et al., Third‐line rescue therapy with levofloxacin is more effective than rifabutin rescue regimen after two Helicobacter pylori treatment failures. Alimentary pharmacology & therapeutics, 2006. 24(10): p. 1469-1474.
[199] Paoluzi, O.A., et al., Low efficacy of levofloxacin-doxycycline-based third-line triple therapy for Helicobacter pylori eradication in Italy. World Journal of Gastroenterology: WJG, 2015. 21(21): p. 6698.
[200] Liou, J.-M., et al., Genotypic resistance in Helicobacter pylori strains correlates with susceptibility test and treatment outcomes after levofloxacin-and clarithromycin-based therapies. Antimicrobial Agents and Chemotherapy, 2011. 55(3): p. 1123-1129.
[201] Matsuzaki, J., et al., Efficacy of sitafloxacin-based rescue therapy for Helicobacter pylori after failures of first-and second-line therapies. Antimicrobial agents and chemotherapy, 2012. 56(3): p. 1643-1645.
[202] Mori, H., et al., Efficacy of 10‐day sitafloxacin‐containing third‐line rescue therapies for Helicobacter pylori strains containing the gyrA mutation. Helicobacter, 2016. 21(4): p. 286-294.
[203] Murakami, K., et al., Multi-center randomized controlled study to establish the standard third-line regimen for Helicobacter pylori eradication in Japan. Journal of Gastroenterology, 2013. 48(10): p. 1128-1135.
[204] Mori, H., et al., Acquisition of double mutation in gyrA caused high resistance to sitafloxacin in Helicobacter pylori after unsuccessful eradication with sitafloxacin-containing regimens. United European gastroenterology journal, 2018. 6(3): p. 391-397.
[205] Ciccaglione, A.F., et al., Rifabutin containing triple therapy and rifabutin with bismuth containing quadruple therapy for third‐line treatment of Helicobacter pylori infection: two pilot studies. Helicobacter, 2016. 21(5): p. 375-381.
[206] Gisbert, J. and X. Calvet, rifabutin in the treatment of refractory Helicobacter pylori infection. Alimentary pharmacology & therapeutics, 2012. 35(2): p. 209-221.
[207] Mori, H., et al., Rifabutin-based 10-day and 14-day triple therapy as a third-line and fourth-line regimen for Helicobacter pylori eradication: a pilot study. United European gastroenterology journal, 2016. 4(3): p. 380-387.
[208] Lim, H.C., et al., Rifabutin‐based high‐dose proton‐pump inhibitor and amoxicillin triple regimen as the rescue treatment for Helicobacter pylori. Helicobacter, 2014. 19(6): p. 455-461.
[209] Nishizawa, T., et al., Dual therapy for third-line Helicobacter pylori eradication and urea breath test prediction. World Journal of Gastroenterology: WJG, 2012. 18(21): p. 2735.
[210] Miehlke, S., et al., Randomized trial of rifabutin‐based triple therapy and high‐dose dual therapy for rescue treatment of Helicobacter pylori resistant to both metronidazole and clarithromycin. Alimentary pharmacology & therapeutics, 2006. 24(2): p. 395-403.
[211] Okimoto, K., et al., Efficacy of levofloxacin based triple and high-dose PPI-amoxicillin dual eradication therapy for Helicobacter pylori after failures of first-and second-line therapies. International Scholarly Research Notices, 2014. 2014.
[212] Nishizawa, T., et al., Effects of patient age and choice of antisecretory agent on success of eradication therapy for Helicobacter pylori infection. Journal of Clinical Biochemistry and Nutrition, 2017. 60(3): p. 208-210.
[213] Sachs, G. and D.R. Scott, Helicobacter pylori: eradication or preservation. F1000 medicine reports, 2012. 4.
[214] Adachi, M., et al., Reinfection rate following effective therapy against Helicobacter pylori infection in Japan. Journal of gastroenterology and hepatology, 2002. 17(1): p. 27-31.
[215] Zendehdel, N., et al., Helicobacter pylori reinfection rate 3 years after successful eradication. Journal of gastroenterology and Hepatology, 2005. 20(3): p. 401-404.
[216] Ryu, K.H., et al., Reinfection rate and endoscopic changes after successful eradication of Helicobacter pylori. World journal of gastroenterology: WJG, 2010. 16(2): p. 251.
[217] Wheeldon, T.U., et al., Long‐term follow‐up of Helicobacter pylori eradication therapy in Vietnam: reinfection and clinical outcome. Alimentary pharmacology & therapeutics, 2005. 21(8): p. 1047-1053.
[218] Seo, M., et al., Recurrence of Helicobacter pylori infection and the long-term outcome of peptic ulcer after successful eradication in Japan. Journal of clinical gastroenterology, 2002. 34(2): p. 129-134.
[219] Matysiak-Budnik, T. and F. Megraud, Epidemiology of Helicobacter pylori infection with special reference to professional risk. Journal of physiology and pharmacology: an official journal of the Polish Physiological Society, 1997. 48: p. 3-17.
[220] Williams, C., Helicobacter pylori and endoscopy. Journal of Hospital Infection, 1999. 41(4): p. 263-268.
